Scrianen folic acid tablets, which are mainly used to prevent birth defects such as neural tube malformations, are the result of a 13-year, $20 million collaboration between the Chinese and American governments and 250,000 clinical observations. The results have been adopted by more than 50 countries in the world, and have been successively published in well-known peer-reviewed journals at home and abroad, such as The Lancet, The New England Journal of Medicine, the Chinese Medical Journal, and the Chinese Journal of Epidemiology. In 1997, the quality standard of 0.4mg folic acid proposed by the company was set as an international standard by the World Health Organization and was recorded by the Chinese Pharmacopoeia. In the same year, "Scrianen folic acid tablet" won the new drug certificate of the Ministry of Health, and was promoted to the whole country as a key project of "100 scientific and technological achievements in ten years" by the Ministry of Health of China. In 2003, it won the national Key new product certificate jointly issued by the Ministry of Science and Technology and other ministries and commissions, and was rated as "National key new product" by the Ministry of Science and Technology, the Ministry of Commerce and other five ministries.

Scrianen folic acid tablet is a drug, the main role is to prevent fetal neural tube malformations (anencephaly, spina bifida); Prevention of fetal cleft lip and palate; Prevent birth defects such as congenital heart disease and other body surface malformations; Prevent anemia in pregnant women, nursing mothers and fetuses

1, can prevent chronic cardiovascular disease such as coronary heart disease.

2, can prevent Alzheimer's disease and other cancers, reduce the incidence.

3. Reduce and prevent the incidence of breast and cervical cancer in women.

4. Prevention and treatment of megaloblastic anemia caused by drugs.

5. Promote the development of fetal nervous system.

6. Reduce the infant mortality rate.

7, reduce pregnancy reaction.